J Intensive Care Med . Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenovi

[tetano]

J Intensive Care Med


. 2022 Aug 17;8850666221121589.
doi: 10.1177/08850666221121589. Online ahead of print.
Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1 nCoV-19, Vaxzevria)


Kelvin Ehikhametalor[SUP] 1 [/SUP], Jacqueline Deans-Minott[SUP] 2 [/SUP], Jacqueline P Duncan[SUP] 3 [/SUP]



Affiliations

• PMID: 35979616
• DOI: 10.1177/08850666221121589

Abstract

The clinical spectrum of Coronavirus 2019 (COVID-19) includes acute COVID-19, long covid and multisystem inflammatory syndrome in children and adults (MISC/A). The rapid roll-out of COVID-19 vaccination has the potential to affect the clinical presentation of COVID-19 and case reports document rare occurrences of MIS-A after COVID-19 infection and recent vaccination with m-RNA vaccines. We describe 2 cases of MIS-A after COVID-19 infection and recent vaccination with ChAdOx1 nCoV-19.

Keywords: COVID-19 vaccine; adverse events; coronavirus 2019; multisystem inflammatory syndrome in adults.